Raymond James Financial
IMNM icon

Raymond James Financial’s Immunome IMNM Stock Holding History

Raymond James Financial’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11M Buy
96,374
+49,805
+107% +$1.11M ﹤0.01% 3325
2025
Q4 		$1M Buy
46,569
+36,269
+352% +$637K ﹤0.01% 3773
2025
Q3 		$121K Buy
10,300
+6,459
+168% +$64.3K ﹤0.01% 4721
2025
Q2 		$35.7K Sell
3,841
-8,209
-68% -$67.3K ﹤0.01% 5315
2025
Q1 		$81.1K Sell
12,050
-13,767
-53% -$132K ﹤0.01% 4582
2024
Q4 		$274K Buy
+25,817
New +$312K ﹤0.01% 4236

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Raymond James Financial's IMNM Position: Q1 2026 in Review

Raymond James Financial increased its Immunome (IMNM) stake by 107% in Q1 2026, buying an estimated $1.11M and bringing the position to 96,374 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3325.

Raymond James Financial first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Raymond James Financial held 96,374 shares of Immunome worth $2.11M as of Q1 2026.
  • Raymond James Financial bought 49,805 Immunome shares in Q1 2026, an estimated $1.11M.
  • Immunome made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3325 holding.
  • Raymond James Financial first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.